Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer

Summary

This trial is a Phase I open-label safety study of Prolanta™, a recombinant analog of the human prolactin protein with a single amino acid substitution to create an antagonist of the prolactin receptor. The Sponsor believes that blocking the prolactin receptor in patients with ovarian and other cancers will be effective as a monotherapy or in combination with other chemotherapies. This Phase I study will be conducted in Subjects with recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Timeline

Start

2016-02

Primary completion

2019-02

Completion

2019-02

Drugs

Indications